For research use only. Not for therapeutic Use.
Solifenacin succinate（Cat No.:I009551）is a muscarinic receptor antagonist primarily used to treat overactive bladder (OAB) symptoms, including urinary urgency, frequency, and incontinence. It works by selectively blocking the M3 muscarinic receptors in the bladder, reducing involuntary contractions and promoting bladder relaxation. This helps alleviate the symptoms of OAB. Solifenacin succinate is typically taken orally in tablet form and has a favorable side-effect profile compared to other anticholinergic medications. Its use is contraindicated in patients with certain conditions, such as narrow-angle glaucoma, and it requires careful monitoring in individuals with renal or hepatic impairments.
| Catalog Number | I009551 |
| CAS Number | 242478-38-2 (succinate) |
| Synonyms | YM 905; YM-905; YM905; Solifenacin succinate; brand name: Vesikur; Vesicare.;[(3R)-1-azabicyclo[2.2.2]octan-3-yl] (1S)-1-phenyl-3,4-dihydro-1H-isoquinoline-2-carboxylate;butanedioic acid |
| Molecular Formula | C27H32N2O6 |
| Purity | ≥95% |
| Target | Neuronal Signaling |
| Solubility | Soluble in DMSO, not in water |
| Storage | 0 - 4 °C for short term, or -20 °C for long term |
| IUPAC Name | [(3R)-1-azabicyclo[2.2.2]octan-3-yl] (1S)-1-phenyl-3,4-dihydro-1H-isoquinoline-2-carboxylate;butanedioic acid |
| InChI | InChI=1S/C23H26N2O2.C4H6O4/c26-23(27-21-16-24-13-10-18(21)11-14-24)25-15-12-17-6-4-5-9-20(17)22(25)19-7-2-1-3-8-19;5-3(6)1-2-4(7)8/h1-9,18,21-22H,10-16H2;1-2H2,(H,5,6)(H,7,8)/t21-,22-;/m0./s1 |
| InChIKey | RXZMMZZRUPYENV-VROPFNGYSA-N |
| SMILES | C1CN2CCC1[C@H](C2)OC(=O)N3CCC4=CC=CC=C4[C@@H]3C5=CC=CC=C5.C(CC(=O)O)C(=O)O |
| Reference | </br>1:Efficacy and Safety of Gabapentin in Comparison to Solifenacin Succinate in Adult Overactive Bladder Treatment. Chua ME, See MC 4th, Esmeňa EB, Balingit JC, Morales ML Jr.Low Urin Tract Symptoms. 2017 Feb 2. doi: 10.1111/luts.12152. [Epub ahead of print] PMID: 28150436 </br>2:Efficacy and safety of tamsulosin hydrochloride 0.2 mg and combination of tamsulosin hydrochloride 0.2 mg plus solifenacin succinate 5 mg after transurethral resection of the prostate: a prospective, randomized controlled trial. Shin YS, Zhang LT, You JH, Choi IS, Zhao C, Park JK.Clin Interv Aging. 2016 Sep 19;11:1301-1307. eCollection 2016. PMID: 27698559 Free PMC Article</br>3:Efficacy and Safety of Solifenacin Succinate Tablets Versus Solifenacin Succinate Tablets With Local Oestrogen for Overactive Bladder in Post-Menopausal Women – A Multi-Centre, Randomised, Open, Controlled Comparison Study. Zhu L, Jiang F.J Minim Invasive Gynecol. 2015 Nov-Dec;22(6S):S243. doi: 10.1016/j.jmig.2015.08.852. Epub 2015 Oct 15. No abstract available. PMID: 27679165 </br>4:Long-term prospective study of the persistence of solifenacin succinate in previously untreated Japanese female patients with overactive bladder. Tanaka Y, Tanuma Y, Masumori N.Int J Urol. 2016 Oct;23(10):866-872. doi: 10.1111/iju.13174. Epub 2016 Aug 12. PMID: 27520420 </br>5:Comparison of Therapeutic Efficacy and Urodynamic Findings of Solifenacin Succinate versus Mirabegron in Women with Overactive Bladder Syndrome: Results of a Randomized Controlled Study. Vecchioli Scaldazza C, Morosetti C.Urol Int. 2016;97(3):325-329. Epub 2016 Apr 20. PMID: 27092789 </br>6:Efficacy and safety of solifenacin succinate tablets versus solifenacin succinate tablets with local estrogen for the treatment of overactive bladder in postmenopausal women–a multicenter, randomized, open-label, controlled comparison study. Jiang F, Zhu L, Xu T, Gong MY, Huang YL, Li HF, Wang JJ, Tong XW, Cheng XX, Bai WP, Li X, Xu XX, Xu HC.Menopause. 2016 Apr;23(4):451-7. doi: 10.1097/GME.0000000000000574. PMID: 26757270 </br>7:Randomized, controlled pilot trial of solifenacin succinate for overactive bladder in Parkinson/’s disease. Zesiewicz TA, Evatt M, Vaughan CP, Jahan I, Singer C, Ordorica R, Salemi JL, Shaw JD, Sullivan KL; Non-Motor Working Group of the Parkinson Study Group (PSG)..Parkinsonism Relat Disord. 2015 May;21(5):514-20. doi: 10.1016/j.parkreldis.2015.02.025. Epub 2015 Mar 6. PMID: 25814050 </br>8:The therapeutic effect of solifenacin succinate on the recovery from voiding dysfunction after radical prostatectomy in men with clinically localized prostate cancer: a prospective, randomized, controlled study. Shim M, Kim J, Park S, Choi SK, Lee SM, Huh KO, Song C, Choo MS, Ahn H.Urology. 2015 May;85(5):1123-9. doi: 10.1016/j.urology.2015.01.022. Epub 2015 Mar 4. PMID: 25746580 </br>9:A comparative study on the efficacy of solifenacin succinate in patients with urinary frequency with or without urgency. Han JY, Lee KS, Park WH, Park CH, Lee JG, Lee JZ, Kim DY, Na YG, Kwon DD, Choo MS.PLoS One. 2014 Nov 17;9(11):e112063. doi: 10.1371/journal.pone.0112063. eCollection 2014. PMID: 25401784 Free PMC Article</br>10:A randomized, double-blind, solifenacin succinate versus placebo control, phase 4, multicenter study evaluating urinary continence after robotic assisted radical prostatectomy. Bianco FJ, Albala DM, Belkoff LH, Miles BJ, Peabody JO, He W, Bradt JS, Haas GP, Ahlering TE.J Urol. 2015 Apr;193(4):1305-10. doi: 10.1016/j.juro.2014.09.106. Epub 2014 Oct 2. PMID: 25281778 |
.gif)